Patent DE-102012011249-A1 (DE)
Title: Ex vivo reprogramming of cells from somatic differentiated vertebrates to high pluripotent cell, comprises isolating autologous cell lines with reprogramming capacity having a marker combination e.g. susceptibility to herpes virus
IPC: C12N5/0789
Filed: 2012-06-06
Abstract: Physiological ex vivo reprogramming of cells from somatic differentiated vertebrates to high pluripotent cells, comprises isolating autologous cell lines with physiological reprogramming capacity, proliferating the isolated cells with the physiological reprogramming capacity in vitro in serum-containing or serum-free media that is supplemented with phospholipoproteins, and performing cocultivation of the isolated cells with a second cell type such as Rodlet cells for conditioning the isolation and in vitro proliferation of cells. Physiological ex vivo reprogramming of cells from somatic differentiated vertebrates to high pluripotent cells, comprises isolating autologous cell lines, with physiological reprogramming capacity, comprising a marker combination of (a) expression of oct 4, (b) susceptibility to herpes virus, (c) expression of aro b, (d) flexibility, (e) differentiation of membrane channels and (f) self-renewal without previous hybridization with tumor cells, proliferating the isolated cells with the physiological reprogramming capacity in vitro in serum-containing or serum-free media that is supplemented with phospholipoproteins, and performing cocultivation of the isolated cells with a second cell type such as Rodlet cells for conditioning the isolation and in vitro proliferation of cells to the effect that they are integrated after reimplantation into a target tissue in the differential mode of division in the target tissues and pass through the typical target tissue differentiation. Independent claims are included for: (1) primary and continuous cell cultures of stem cell lines that are cultured by the method and are obtained using vitellogenin-homologous/-orthologous proteins and/or using estradiol supplementation in tissue hormone-typical concentrations (greater than 100 ng/l) with and without hormone treatment of donor organisms; (2) a model organism for providing transplantable cell lines for implementing the method, where the model organism is a gyno-genetically, genetically uniform goldfish or carp-clone, and stem cells according to the marker combination of (a)-(f) are autologous implanted from an individual clone after isolation, extracorporeal propagation, label and experimental manipulation of the cells in any of the individual clone; (3) diagnostics agents, therapeutics agents and method based on the specific mechanism of transfer of information via neural crest, where the agents are cultured from the isolation and chemical characterization of specific cell components from the cell culture systems, and reinterpretation of molecular mechanisms is derived; (4) the therapeutic agents in a region of cancer medicine, where the agents are prevented using ingredients of the Rodlet cells as cytotoxic agents for controlling malignant residual tissue after the removal of tumor; and (5) method within tumor diagnostics, where a biopsy material is co cultured from a neoplasia suspected tumor with the transgenic cell line, which expresses the green fluorescent proteins after exogenous transfer of transcription factor of oct 4.